Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

 Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

Shots:

  • Bayer, BMS and Ono collaborate to evaluate the combination of Bayer’s Stivarga (regorafenib) with BMS & Ono’s Opdivo (nivolumab) vs regorafenib in patients with micro-satellite stable mCRC
  • The collaboration follows safety data of regorafenib as 3L monothx. in P-III CORRECT study and the efficacy data of P-I REGONIVO study evaluating the combination of regorafenib and nivolumab in Japan
  • Stivarga is an oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic receptor tyrosine kinase and is an approved therapy for patients with hepatocellular carcinoma prior treated with Nexavar. Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s own immune system against cancer

Click here to read full press release/ article | Ref: BMS | Image: KOAM

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post